• Company
  • News
  • Investors
  • Contacts
  • Careers
polypeptide-logopolypeptide-logologo-mobilepolypeptide-logo
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
✕
  • Home
  • News
  • Expert views
  • PolyPeptide participates in industry effort to advance sustainability

PolyPeptide participates in industry effort to advance sustainability

26 March 2024
Expert views

Increasing manufacturing volume requirements and the high process mass intensity (PMI) of peptide synthesis warrants continued industry efforts for more sustainable production processes. PolyPeptide collaborated with other members of the American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable (ACSGCIPR) to compile and analyze PMI metrics for 40 synthetic peptide processes at various development stages. This comprehensive data assessment revealed various concrete opportunities to optimize the environmental footprint by advancing manufacturing technologies.

Read the article here

 

Published by American Chemical Society American Chemical Society (acs.org)
Publication Date:March 20, 2024
https://doi.org/10.1021/acs.joc.3c01494
Ivy Kekessie, Katarzyna Wegner, Isamir Martinez, Michael E. Kopach, Timothy D. White, Janine K. Tom, Martin N. Kenworthy, Fabrice Gallou, John Lopez, Stefan G. Koenig, Philippa R. Payne Philippa R. Payne Outsourced Manufacturing, Pharmaceutical Development & Manufacturing, Gilead Alberta ULC, 1021 Hayter Rd NW, Edmonton, T6S 1A1, Canada More by Philippa R. Payne, Stefan Eissler, Balasubramanian Arumugam, Changfeng Li, Subha Mukherjee, Albert Isidro-Llobet, Olivier Ludemann-Hombourger, Paul Richardson, Jörg Kittelmann, Daniel Sejer Pedersen, and Leendert J. van den Bos

 

Back to news

Related posts

2 April 2025

Expanding the Reach of Sustainable Solid-Phase Peptide Synthesis


Read more
20 March 2025

Impurities in Peptide Drug Substance and Challenges Faced during Registration (in US, EU, Brazil and China Markets) and Commercial Phase


Read more
13 November 2024

Peptide Manufacturing: Rethinking the Technology Platform for Large Scale Demand


Read more

Polypeptide Group

INFO

COMPANY
LEADERSHIP
CONTACTS
CAREERS

NEWS

LATEST NEWS
SIGN UP FOR NEWS
EVENTS

SOCIALS

LINKEDIN
YOUTUBE
© Confidentiality 2025 PolyPeptide Group • Cookie Policy • Sitemap • Privacy policy
    • Company
    • News
    • Investors
    • Contacts
    • Careers